Liquidia (LQDA) Depreciation & Amortization (CF) (2020 - 2026)
Liquidia's (LQDA) quarterly Depreciation & Amortization (CF) came in at $497000.0 in Q1 2026, up 10.2% year-on-year from $451000.0 in Q1 2025, and up 55.31% quarter-over-quarter from $320000.0 in Q4 2025.
Liquidia (LQDA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Liquidia's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $497000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 10.2% year-over-year to $497000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 27.1% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 30.45% from the prior year.
- Depreciation & Amortization (CF) grew to $497000.0 in Q1 2026 per LQDA's latest filing, from $320000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q3 2022 and bottomed at $281000.0 in Q2 2025.
- The 5-year median for Depreciation & Amortization (CF) is $518000.0 (2024), against an average of $591000.0.
- Across the five-year window, Depreciation & Amortization (CF) tumbled 54.43% in 2023 and climbed 18.68% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $566000.0 in 2022, then fell by 10.6% to $506000.0 in 2023, then grew by 2.37% to $518000.0 in 2024, then sank by 38.22% to $320000.0 in 2025, then jumped by 55.31% to $497000.0 in 2026.
- Per Business Quant, the three latest LQDA Depreciation & Amortization (CF) figures stand at $497000.0 (Q1 2026), $320000.0 (Q4 2025), and $476000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 497,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 497,000.00 |
| Mar 31, 2026 | 497,000.00 |
| Dec 31, 2025 | 320,000.00 |
| Dec 31, 2025 | 320,000.00 |
| Sep 30, 2025 | 476,000.00 |
| Sep 30, 2025 | 476,000.00 |
| Jun 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 281,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Dec 31, 2024 | 518,000.00 |
| Dec 31, 2024 | 518,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 580,000.00 |
| Jun 30, 2024 | 580,000.00 |
| Mar 31, 2024 | 489,000.00 |
| Mar 31, 2024 | 489,000.00 |
| Dec 31, 2023 | 506,000.00 |
| Dec 31, 2023 | 506,000.00 |